MedTrace Logo

A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis

NCT06158490 · Status: ENROLLING_BY_INVITATION · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-03-20

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the efficacy and safety of JYP0061 in adult patients with moderate-to-severe atopic dermatitis. The main questions it aims to answer are:

* The efficacy of JYP0061 in treating adult patients with moderate-to-severe atopic dermatitis.
* The safety profile of JYP0061 when administered to adult patients with moderate-to-severe atopic dermatitis.

Participants will:

* Be treated with either a low-dose or high-dose of JYP0061.
* Undergo efficacy and safety evaluations as stipulated in the trial protocol.

Conditions

Interventions

DRUG

JYP0061 15 mg

Participants in the JYP0061 15 mg group will receive a 15 mg oral tablet of JYP0061 once daily for 12 weeks.

DRUG

JYP0061 30 mg

articipants in the JYP0061 30 mg group will receive a 30 mg oral tablet of JYP0061 once daily for 12 weeks.

DRUG

Placebo

Participants in the placebo group will receive a matching placebo tablet once daily for 12 weeks.

Sponsors & Collaborators

  • Guangzhou JOYO Pharma Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-27
Primary Completion
2026-02-10
Completion
2026-10-10

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06158490 on ClinicalTrials.gov